Previous research has suggested that patients with classical Hodgkin lymphoma who are refractory to or relapse after first-line therapy may be more likely to be cured after receiving second-line salvage chemotherapy followed by autologous stem cell transplantation (ASCT) than after receiving standard-dose chemotherapy.1,2 High complete remission rates prior to ASCT have been shown to predict better long-term outcomes for patients with the condition.3 Researchers have investigated a number of combination therapy regimens as induction regimens prior to ASCT for refractory to or relapsed lymphoma, yielding pre-ASCT CR rates ranging from 20% to 54% and overall response rates (ORRs) of 60% to 80%.4 A prospective multicenter single-arm phase 2 study also indicated that the combination of bendamustine, gemcitabine, and vinorelbine (BEGEV) as second-line chemotherapy before ASCT, in 59 patients with relapsed/refractory (R/R) classical Hodgkin lymphoma, resulted in a CR of 73% and ORR of 83%.5 Now, updated 5-year results from that same study have confirmed the benefits, showing a CR rate of 75% and ORR of 83%.6 But experts cautioned that a randomized trial would be needed to determine whether the regimen is superior to other treatments. The update[d] 5-year results of BEGEV (bendamustine, gemcitabine, vinorelbine) followed by autologous stem cell transplantation in patients with Hodgkin disease refractory or relapsing to first-line therapy confirm the significant data in terms of CR rate (75%) as well as PFS (59%) and overall survival (78%), lead study author Armando Santoro, MD, director of the Cancer Center at Humanitas Research Hospital, Milan, said in an email Continue reading →

Conference Call and Webcast @ 8:00 a.m. Eastern Time Today NEW YORK, Feb Continue reading →

NEW YORK, Feb. Continue reading →

Whenever Harry Wuest has a doctors appointment in northern Atlantas hospital cluster dubbed Pill Hill, he makes sure to stop by the office of Dr. Douglas Doug Murphy for a quick chat. And Murphy, unless hes tied up in the operating room, always takes a few minutes to say hello to his former patient. Continue reading →

According to a report published by TMR market, the Hematopoietic Stem Cell Transplantation (HSCT) economy is expected to witness a CAGR growth of XX% within the forecast period (2019-2029) and reach at a value of ~US$ at the ending of 2029. The macro-economic and micro elements which are predicted to influence the trajectory of this market are studied in the presented market study. Light on the raw material throws Suppliers, vendors, manufacturers, and market consumers at the markets value chain Continue reading →

- First conditional approval of ZYNTEGLOTM (autologous CD34+ cells encoding A-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent -thalassemia who do not have 0/0 genotype in Europe achieved in 2019; Germany launch underway - Announced positive top-line data from pivotal Phase 2 KarMMa study of ide-cel in relapsed and refractory multiple myeloma - Presented clinical data across studies of LentiGlobin gene therapy for -thalassemia (betibeglogene autotemcel) and LentiGlobin gene therapy for sickle cell disease (SCD) and bb21217 in multiple myeloma at American Society of Hematology (ASH) Annual Meeting - Ended quarter with $1.24 billion in cash, cash equivalents and marketable securities bluebird bio, Inc. Continue reading →

Cellular Dynamics International. Continue reading →

(MENAFN - GetNews) Age Stop Switzerland introduces a path-breaking line of anti-aging creams that combines science with innovative and natural ingredients. Continue reading →